We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
NVO's Hemophilia A Treatment Gets EC Nod, Data Presented on CagriSema
Read MoreHide Full Article
Key Takeaways
Novo wins EU approval for Frehemgo to prevent bleeding episodes in adults and children with hemophilia A.
CagriSema delivers estimated weight loss of 20.7-21.0% at 68 weeks versus 2.0% for placebo.
Novo faces mounting competition from Lilly, while CagriSema's FDA decision is expected in Q4 2026.
Novo (NVO - Free Report) announced that the European Commission (EC) has granted marketing authorization for Frehemgo (denecimig) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with hemophilia A, with or without inhibitors.
The approval follows a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in September 2026.
Frehemgo is a next-generation factor VIIIa (FVIIIa)-mimetic bispecific antibody administered subcutaneously. It offers flexible dosing options, allowing patients and healthcare providers to choose between once-weekly, every-two-weeks or once-monthly administration through a single-use prefilled pen.
The approval is based on results from the FRONTIER clinical trial program.
The drug is under FDA review in the United States.
NVO Presents Data on CagriSema
Novo announced primary results from the phase III REDEFINE 9 study of investigational CagriSema in adults with overweight or obesity.
CagriSema is an investigational fixed-dose combination of a long-acting amylin analog, cagrilintide, and the GLP-1 receptor agonist, semaglutide.
NVO is evaluating once-weekly subcutaneous CagriSema as a treatment for adults with overweight or obesity (REDEFINE program) and as a treatment for adults with type 2 diabetes (REIMAGINE program).
REDEFINE 9 was a 68-week phase III, placebo-controlled study, double-blind within dose levels, evaluating the efficacy and safety of once-weekly CagriSema 1.7 mg / 1.7 mg and 1.0 mg / 1.0 mg in 309 adults with obesity (BMI ≥30 kg/m2), or overweight (BMI ≥27 kg/m2) with one or more obesity-related complications, and without diabetes.
Results from the study showed CagriSema 1.7 mg / 1.7 mg and 1.0 mg / 1.0 mg produced estimated average weight loss of 20.7% and 21.0%, respectively, at 68 weeks, compared with 2.0% with placebo, in adults with overweight or obesity, if all patients stayed on treatment.
The results were presented at ObesityWeek 2026 in Washington, DC, US.
Details on NVO’s REDEFINE 1 Study
NVO also announced results from two post hoc analyses of the phase III REDEFINE 1 study of investigational CagriSema.
The analysis revealed that 67.8% of adults treated with investigational CagriSema 2.4 mg/ 2.4 mg were early responders, achieving at least 5% weight loss by week eight. Women were more likely to be early responders than delayed responders (71.8% vs. 59.5%).
A separate post hoc analysis of REDEFINE 1 showed that a significantly higher proportion of adults with overweight or obesity treated with investigational CagriSema (2.4 mg/2.4 mg) reported meaningful improvements in physical function at week 68 compared with those receiving placebo.
Novo submitted a new drug application to the FDA in December 2025 seeking approval of CagriSema 2.4 mg/2.4 mg for weight management, with a regulatory decision expected in the fourth quarter of 2026.
NVO Looking to Turnaround Business
Earlier this month, NVO reported better-than-expected third-quarter 2026 results. Adjusted operating profit rose 27% at constant exchange rates (CER), aided partly by a favorable year-ago comparison.
Novo Nordisk A/S Price, Consensus and EPS Surprise
More importantly, Novo raised its 2026 adjusted sales and operating profit growth outlook to a range of a 2% decline to a 2% increase, from a 6% decline to flat growth, reflecting higher GLP-1 sales expectations. The upbeat guidance boosted investor confidence.
Strong uptake of Wegovy pill also supported the momentum. Continued international expansion and improving patient access could further support growth amid pricing pressures on injectable products.
Novo shares have gained 8.4% in the past month compared with the industry’s 10.5% growth.
Image Source: Zacks Investment Research
Nonetheless, intense competition from Eli Lilly (LLY - Free Report) , persistent pricing pressures and weakness in its diabetes franchise remain major concerns.
Lilly continues to demonstrate strong commercial momentum, with its third-quarter 2026 revenues surging 39% year over year, driven by robust demand for Mounjaro [for type II diabetes (T2D)] and Zepbound (for obesity). Zepbound sales jumped 49%, underscoring the growing competitive threat to Wegovy in the injectable obesity market.
Lilly's newly launched oral obesity drug, Foundayo, also poses a challenge to the Wegovy pill, while broader treatment access could further intensify the rivalry.
Shares of Novartis have risen 16.4% so far this year. The Zacks Consensus Estimate for 2027 earnings has risen from $9.81 to $9.99 per share over the past 30 days.
Image: Shutterstock
NVO's Hemophilia A Treatment Gets EC Nod, Data Presented on CagriSema
Key Takeaways
Novo (NVO - Free Report) announced that the European Commission (EC) has granted marketing authorization for Frehemgo (denecimig) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adults and children with hemophilia A, with or without inhibitors.
The approval follows a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) in September 2026.
Frehemgo is a next-generation factor VIIIa (FVIIIa)-mimetic bispecific antibody administered subcutaneously. It offers flexible dosing options, allowing patients and healthcare providers to choose between once-weekly, every-two-weeks or once-monthly administration through a single-use prefilled pen.
The approval is based on results from the FRONTIER clinical trial program.
The drug is under FDA review in the United States.
NVO Presents Data on CagriSema
Novo announced primary results from the phase III REDEFINE 9 study of investigational CagriSema in adults with overweight or obesity.
CagriSema is an investigational fixed-dose combination of a long-acting amylin analog, cagrilintide, and the GLP-1 receptor agonist, semaglutide.
NVO is evaluating once-weekly subcutaneous CagriSema as a treatment for adults with overweight or obesity (REDEFINE program) and as a treatment for adults with type 2 diabetes (REIMAGINE program).
REDEFINE 9 was a 68-week phase III, placebo-controlled study, double-blind within dose levels, evaluating the efficacy and safety of once-weekly CagriSema 1.7 mg / 1.7 mg and 1.0 mg / 1.0 mg in 309 adults with obesity (BMI ≥30 kg/m2), or overweight (BMI ≥27 kg/m2) with one or more obesity-related complications, and without diabetes.
Results from the study showed CagriSema 1.7 mg / 1.7 mg and 1.0 mg / 1.0 mg produced estimated average weight loss of 20.7% and 21.0%, respectively, at 68 weeks, compared with 2.0% with placebo, in adults with overweight or obesity, if all patients stayed on treatment.
The results were presented at ObesityWeek 2026 in Washington, DC, US.
Details on NVO’s REDEFINE 1 Study
NVO also announced results from two post hoc analyses of the phase III REDEFINE 1 study of investigational CagriSema.
The analysis revealed that 67.8% of adults treated with investigational CagriSema 2.4 mg/ 2.4 mg were early responders, achieving at least 5% weight loss by week eight. Women were more likely to be early responders than delayed responders (71.8% vs. 59.5%).
A separate post hoc analysis of REDEFINE 1 showed that a significantly higher proportion of adults with overweight or obesity treated with investigational CagriSema (2.4 mg/2.4 mg) reported meaningful improvements in physical function at week 68 compared with those receiving placebo.
Novo submitted a new drug application to the FDA in December 2025 seeking approval of CagriSema 2.4 mg/2.4 mg for weight management, with a regulatory decision expected in the fourth quarter of 2026.
NVO Looking to Turnaround Business
Earlier this month, NVO reported better-than-expected third-quarter 2026 results. Adjusted operating profit rose 27% at constant exchange rates (CER), aided partly by a favorable year-ago comparison.
Novo Nordisk A/S Price, Consensus and EPS Surprise
Novo Nordisk A/S price-consensus-eps-surprise-chart | Novo Nordisk A/S Quote
More importantly, Novo raised its 2026 adjusted sales and operating profit growth outlook to a range of a 2% decline to a 2% increase, from a 6% decline to flat growth, reflecting higher GLP-1 sales expectations. The upbeat guidance boosted investor confidence.
Strong uptake of Wegovy pill also supported the momentum. Continued international expansion and improving patient access could further support growth amid pricing pressures on injectable products.
Novo shares have gained 8.4% in the past month compared with the industry’s 10.5% growth.
Image Source: Zacks Investment Research
Nonetheless, intense competition from Eli Lilly (LLY - Free Report) , persistent pricing pressures and weakness in its diabetes franchise remain major concerns.
Lilly continues to demonstrate strong commercial momentum, with its third-quarter 2026 revenues surging 39% year over year, driven by robust demand for Mounjaro [for type II diabetes (T2D)] and Zepbound (for obesity). Zepbound sales jumped 49%, underscoring the growing competitive threat to Wegovy in the injectable obesity market.
Lilly's newly launched oral obesity drug, Foundayo, also poses a challenge to the Wegovy pill, while broader treatment access could further intensify the rivalry.
NVO’s Zacks Rank and A Stock to Consider
Novo currently carries a Zacks Rank #3 (Hold). A better-ranked large-cap pharma stock is Novartis (NVS - Free Report) , which currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Shares of Novartis have risen 16.4% so far this year. The Zacks Consensus Estimate for 2027 earnings has risen from $9.81 to $9.99 per share over the past 30 days.